MedTrace Logo

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

NCT00000922 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1710

Last updated 2014-04-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether it is better to start an anti-HIV regimen containing a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a PI in combination with an NNRTI. This study will also examine which treatment regimen is best as a first treatment for HIV infection.

Conditions

  • HIV Infections

Interventions

DRUG

Indinavir sulfate

DRUG

Abacavir sulfate

DRUG

Nelfinavir mesylate

DRUG

Efavirenz

DRUG

Nevirapine

DRUG

Lamivudine

DRUG

Stavudine

DRUG

Didanosine

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Rodger D. MacArthur, MD · University Health Center, Wayne State University

  • Richard Novak, MD · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2003-01-31
Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000922 on ClinicalTrials.gov